We are live on ! Find out more
TXG icon

10x Genomics
TXG

340 hedge funds and large institutions have $15.2B invested in 10x Genomics in 2021 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 157 increasing their positions, 76 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

198% more call options, than puts

Call options by funds: $86.3M | Put options by funds: $29M

107% more repeat investments, than reductions

Existing positions increased: 157 | Existing positions reduced: 76

46% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 46

19% more capital invested

Capital invested by funds: $12.8B → $15.2B (+$2.45B)

7.15% more ownership

Funds ownership: 81.98% → 89.13% (+7.1%)

5% more funds holding

Funds holding: 323 → 340 (+17)

10% less funds holding in top 10

Funds holding in top 10: 10 → 9 (-1)

Holders
340
Holders Change
+17
Holders Change %
+5.26%
% of All Funds
5.92%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.16%
New
67
Increased
157
Reduced
76
Closed
46
Calls
$86.3M
Puts
$29M
Net Calls
+$57.4M
Net Calls Change
+$64.6M

Top Buyers

1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$658M
2
BlackRock
BlackRock
New York
+$406M
3
AIM
ARK Investment Management
Florida
+$144M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$99.8M
5
BCM
Brown Capital Management
Maryland
+$99.6M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$334M
2
FCMI
Foresite Capital Management II
California
-$90.5M
3
N
Nuveen
North Carolina
-$71.3M
4
MCAV
Meritech Capital Associates V
California
-$59.6M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$58.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.55B -$334M -1,843,937 -19%
BlackRock
2
BlackRock
New York
$1.48B +$406M +2,242,036 +42%
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.39B +$99.8M +551,232 +8%
Baillie Gifford & Co
4
Baillie Gifford & Co
United Kingdom
$985M +$658M +3,634,870 +260%
Morgan Stanley
5
Morgan Stanley
New York
$847M +$34.7M +191,777 +5%
AIM
6
ARK Investment Management
Florida
$842M +$144M +795,916 +23%
1WCM
7
12 West Capital Management
New York
$376M – – –
MCAV
8
Meritech Capital Associates V
California
$351M -$59.6M -329,485 -16%
FCMI
9
Foresite Capital Management II
California
$343M -$90.5M -500,000 -22%
Sumitomo Mitsui Trust Group
10
Sumitomo Mitsui Trust Group
Japan
$341M +$93.8M +518,185 +42%
State Street
11
State Street
Massachusetts
$312M +$83.9M +463,597 +41%
NAMA
12
Nikko Asset Management Americas
New York
$299M +$90.2M +498,675 +48%
Ameriprise
13
Ameriprise
Minnesota
$260M -$14.4M -79,485 -6%
CS
14
Credit Suisse
Switzerland
$256M -$3.97M -21,934 -2%
Franklin Resources
15
Franklin Resources
California
$244M +$8.96M +49,530 +4%
BCM
16
Brown Capital Management
Maryland
$241M +$99.6M +550,344 +81%
Invesco
17
Invesco
Georgia
$237M -$17.2M -94,878 -7%
William Blair Investment Management
18
William Blair Investment Management
Illinois
$221M -$4.26M -23,539 -2%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$208M +$42.3M +233,535 +28%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$197M +$19.5M +107,662 +12%
VMV
21
Venrock Management VI
California
$188M – – –
JSP
22
Jackson Square Partners
California
$180M +$13.6M +75,273 +9%
GGHC
23
Gilder Gagnon Howe & Co
New York
$152M -$871K -4,810 -0.6%
Wells Fargo
24
Wells Fargo
California
$150M +$1.55M +8,574 +1%
FCMI
25
Foresite Capital Management I
California
$147M -$45.2M -250,000 -25%
1
2 3 4 5

TXG Hedge Fund Activity: Q2 2021 in Review

340 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2021, worth a combined $15.2B — up 19% from $12.8B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new TXG positions and 46 closed out — a net gain of 21 holders — while 157 added to existing stakes and 76 trimmed.

The largest buyer was Baillie Gifford & Co, adding an estimated $658M. The largest seller was Fidelity Investments, cutting an estimated $334M.

  • 340 institutional investors held 10x Genomics (TXG) as of Q2 2021, up from 323 in Q1 2021.
  • Funds reported $15.2B of 10x Genomics stock for Q2 2021, up 19% quarter-over-quarter.
  • 67 funds opened new 10x Genomics positions in Q2 2021 and 46 closed out, a net change of +21 holders.
  • The largest 10x Genomics buyer in Q2 2021 was Baillie Gifford & Co, an estimated $658M added.
  • The largest 10x Genomics seller in Q2 2021 was Fidelity Investments, an estimated $334M sold.

Based on aggregated 13F filings for Q2 2021.